Orchestra BioMed Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $360.54M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2022 Ended Dec 31, 2022 | Mar 24, 2023 | After market close | – | – | – |
Press releases
Announcements Orchestra BioMed filed with the SEC
Orchestra BioMed Exceeds Full Enrollment Target
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Accelerating high - impact technologies to patients through risk - reward sharing partnerships Corporate Overview | September 2026 Nasdaq : OBIO
Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed to Receive Up to $21 Million
Other events · EX-99.1 to Form 8-K
Quarter 2025 Corporate Update Conference Call
Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed Business Update November 2025 Nasdaq: OBIO
Regulation FD disclosure · EX-99.2 to Form 8-K
This presentation has been prepared for informational purposes only from information
Regulation FD disclosure · EX-99.1 to Form 8-K
Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Orchestra BioMed Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Orchestra BioMed Announces Pricing of $40 Million Public Offering
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Ligand and Medtronic Commit $70 Million in Strategic
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Orchestra BioMed Receives FDA Breakthrough Device
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
KƌĐŚĞƐƚƌĂ ŝŽDĞĚ ŽƌƉŽƌĂƚĞ WƌĞƐĞŶƚĂƚŝŽŶ Y ϭ ϮϬϮϱ
Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed Announces Appointment of Former
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed Announces Appointment of Cardiovascular
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Bringing medical inn vation to life
Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed Corporate Presentation Q1 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed Corporate Presentation Q4 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed Corporate Presentation Q4 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed BACK B EAT September 2023
Regulation FD disclosure · EX-99.2 to Form 8-K
2 | Corporate Presentation Q2 2023
Regulation FD disclosure · EX-99.1 to Form 8-K/A
Orchestra BioMed Corporate Presentation Q2 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Bringing medical inn vation to life Bringing medical inn vation to life Orchestra BioMed Corporate Presentation Q2 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF ORCHESTRA AND THE ACCOMPANYING NOTES AS OF DECEMBER 31, 2022 AND FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Results of operations · EX-99.1 to Form 8-K/A
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF ORCHESTRA AS OF DECEMBER 31, 2022 AND FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021
Results of operations · EX-99.2 to Form 8-K/A
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION AND THE ACCOMPANYING NOTES AS OF AND FOR THE YEAR ENDED DECEMBER 31, 2022
Results of operations · EX-99.3 to Form 8-K/A
Bringing medical inn vation to life Orchestra BioMed Corporate Presentation Q1 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED JANUARY 27, 2023
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION AND THE ACCOMPANYING NOTES AS OF AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 AND FOR THE YEAR DECEMBER 31, 2021
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Bringing medical inn vation to life Orchestra BioMed Corporate Presentation July 2022
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Orchestra BioMed ™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K